My very dear friend and advocate supreme, Jan Manarite, from PCRI has sent me an update on MDV3100 (enzalutamide). As usual her information is important, so I thought I would pass it on today. • She points out that once the FDA approves MDV3100 (I am going to work on the assumption that it will [...]
What are our goals as advanced prostate cancer survivors and what are the goals of our oncologists? Often they are not the same! This misalignment between our expectations and those of our clinicians is common, but inexcusable. These issues become clear when we look at issues surrounding our quality of life. The treatments for advanced [...]
There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval. I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news [...]
One of the more common myths about hormone therapy (ADT) to treat prostate cancer is that its effectiveness will last only for one and a half to two years. For some men this might be true, but it is not a reality in today’s prostate cancer landscape. What makes this myth worse is that it [...]
A subgroup analysis of the phase III trials of Provenge (Sipuleucel-T) suggests that there might be a dramatic role for Provenge in African-American men who have advanced prostate cancer that has become castration-resistant (mCRPC). The analysis, which was released at the American Urological Association 2012 Annual Scientific Meeting, was headed up by Colonel David G. [...]
Johns Hopkins Kimmel Cancer Center along with Danish researchers have announced the development of a novel, investigational anticancer drug (G202) that has been described as a molecular grenade that targets cancer cells. The drug is able to travel undetected by normal cells through the bloodstream until it is activated by a specific cancer proteins, then [...]
It has just been announced that there are now two new additional sites added to the Early/Expanded Access Program for Enzalutamide (MDV3100). The program is technically a clinical trial designed to monitor MDV-3100’s safety in men with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. This means that there are now a total of [...]
At a recent meeting that I attended it was reported by a nurse that one of her patients with advanced prostate cancer with only a PSA recurrence and lymph node involvement on a scan was rejected by their insurance company for reimbursement for Provenge. The insurance company indicated that to pay for the treatment they [...]
Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]
The National Health Service cost regulators for England and Wales have recommended the use of Zytiga in the treatment of men with castrate resistant advanced prostate cancer. The National Institute for Health and Clinical Excellence (NICE) has published a final guidance endorsing Zytiga as an NHS treatment option for men with advanced, metastatic, castration resistant [...]
